This can be compared to the reduced risk for MACE seen in this study after MBS compared to treatment with GLP-1 RA in patients with T2D (HR) adjusted 0.76 (95%CI 0.59–0.98). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.